Background. Estimates for the annual progression rate from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) vary widely. In this explorative study, we quantified how this uncertainty affects the estimates of effectiveness and efficiency of screening and treatment for EAC. Design. We developed 3 versions of the University of Washington / Microsimulation Screening Analysis-EAC model. The models differed with respect to the annual progression rate from BE to EAC (0.12% or 0.42%) and the possibility of spontaneous regression of dysplasia (yes or no). All versions of the model were calibrated to the observed Surveillance, Epidemiology, and End Results esophageal cancer incidence rates from 1998 to 2009. To identify the impact of natural history, we estimated the incidence and deaths prevented as well as numbers needed to screen (NNS) and treat (NNT) of a onetime perfect screening at age 65 years that detected all prevalent BE cases, followed by a perfect treatment intervention. Results. Assuming a perfect screening and treatment
Background. Estimates for the annual progression rate from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) vary widely. In this explorative study, we quantified how this uncertainty affects the estimates of effectiveness and efficiency of screening and treatment for EAC. Design. We developed 3 versions of the University of Washington / Microsimulation Screening Analysis-EAC model. The models differed with respect to the annual progression rate from BE to EAC (0.12% or 0.42%) and the possibility of spontaneous regression of dysplasia (yes or no). All versions of the model were calibrated to the observed Surveillance, Epidemiology, and End Results esophageal cancer incidence rates from 1998 to 2009. To identify the impact of natural history, we estimated the incidence and deaths prevented as well as numbers needed to screen (NNS) and treat (NNT) of a onetime perfect screening at age 65 years that detected all prevalent BE cases, followed by a perfect treatment intervention. Results. Assuming a perfect screening and treatment intervention for all patients with BE, the maximum EAC mortality reduction (64%-66%) and the NNS per death prevented (470-510) were similar across the 3 model versions. However, 3 times more people needed to be treated to prevent 1 death (24 v. 8) in the 0.12% regression model compared with the 0.42% progression model. Restricting treatment to those with dysplasia or only high-grade dysplasia resulted in smaller differences in NNT (2-3 to prevent one EAC case) but wider variation in effectiveness (mortality reduction of 15%-24%). Conclusion. The uncertainty in the natural history of the BE to EAC sequence influenced the estimates of effectiveness and efficiency of BE screening and treatment considerably. This uncertainty could seriously hamper decision making about implementing BE screening and treatment interventions. Key words: Barrett's esophagus; esophageal adenocarcinoma; population-based modeling; progression rates; incidence; screening; prevalence. O ver the past 4 decades, the incidence of esophageal adenocarcinoma (EAC) has rapidly increased. Barrett's esophagus (BE) is a precursor of EAC. 1 In BE, normal cells of the esophagus are replaced by intestinal metaplasia, which may progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), or adenocarcinoma. 2 Despite this concern, little is known about the prevalence of BE in the population and the time course of progression to EAC.
Several unknown crucial characteristics of the epidemiology of the BE to EAC sequence in the population may have large influences on estimates of the effectiveness and efficiency of BE screening and treatment. First, estimates for the annual progression rate from BE to EAC vary widely in the literature, within a range of 0.07% to 3.6%. [3] [4] [5] Until recently, an annual progression rate of 0.42% was assumed most plausible. 6, 7 However, several large recently published population-based studies suggest that the progression rate is actually much lower (~0.12%). [8] [9] [10] Selection bias, publication bias, study size, and differences in follow-up years and cohort characteristics all contribute to the difficulty of comparing and validating these estimates. Second, there are large differences in the estimates of the prevalence of BE in the population (0.34%-25%). 11 Differences in BE definitions over time and between countries are an important bottleneck for obtaining consistent estimates. Third, there are indications that BE with dysplasia might regress. Several studies have shown the disappearance of dysplasia in BE surveillance cohorts. 6, 12 Regression has also been demonstrated in wellconducted studies with expert pathologists. 13 Disappearance perceived in subsequent biopsies could be the result of misclassification because of subjective interpretation of LGD and HGD by pathologists or of sampling errors.
With the introduction of endoscopic mucosal resection and radiofrequency ablation, endoscopic therapy for BE with HGD is being increasingly viewed as a first-line treatment. 14 However, the uncertainty in the natural history of EAC may have large influences on the expected effectiveness and efficiency of such interventions.
In this study, we used microsimulation modeling to explore how uncertainty in the risk of EAC development in patients with BE affects the expected effectiveness and efficiency of screening and treatment intervention.
METHODS

The UW/MISCAN-EAC Model
The University of Washington / Microsimulation Screening Analysis (UW/MISCAN)-EAC model was developed as part of the Cancer Intervention and Surveillance Modeling Network (CISNET). A detailed description can be found in the online appendix. In brief, the model simulates the life histories of a large population of individuals from birth to death. Part of the population has symptomatic gastroesophageal reflux disease (GERD), which is defined as weekly heartburn and/or acid regurgitation. These individuals are at increased risk of developing BE. However, BE can also develop in the absence of GERD symptoms (relative risk [RR] = 6.0 GERD to BE compared with non-GERD to BE, resulting from the assumption that 60% of the patients with BE have symptomatic GERD 5 ). Depending on age, sex, and baseline individual risk, low-grade dysplasia may develop from nondysplastic (ND) BE, which may later progress to high-grade dysplasia. Although most individuals with BE will never develop cancer, malignant cells can arise from HGD, transforming to localized EAC, which can progress sequentially into regional and distant EAC. In each cancer stage, there is a probability of the cancer diagnosis due to the development of symptoms v. staying asymptomatic and progressing undetected into the next stage. Persons may die of other causes at any time during their lifetime ( Figure 1 ).
Model Quantification
To quantify the effect of different natural history assumptions, we developed 3 different model versions: low-progression model, high-progression model, and regression model. The natural history assumption on the progression from BE to EAC is different in each model. Our low-progression model considers a low progression rate from BE (ND 1 LGD) at age 65 years to EAC (0.12% annually within a 5-year follow up), consistent with recently published studies. [15] [16] [17] The high-progression model considers a higher progression rate (0.42% annually), consistent with published reviews. 18-20 These 2 model structures include only progressive transitions. The regression model also includes the possibility to regress from HGD to LGD and from LGD to no dysplasia and considers a low progression rate (0.12% annually from BE [ND 1 LGD] at age 65 years to EAC within a 5-year follow-up). These main contrasts in model structures and the annual progression rate calibration target among the 3 model versions are shown in Table 1 . In addition to the varying progression rates from BE to EAC, all models were calibrated to the age-specific esophageal cancer incidence as observed in the Surveillance, Epidemiology, and End Results (SEER) Program for 1998 to 2009 (without assuming secular trends), the amount of LGD and HGD in the 60-to 65-year-old BE population, and the estimated average sojourn time from undetected to detected EAC for the total EAC population. An overview of all calibration targets and the resulting natural history characteristics for each model version can be found in the online appendix (Table A2 ). The BE prevalence was optimized in each model to match the EAC incidence while accounting for the differences in progression rates and model structure assumptions.
Perfect Screening and Perfect Treatment Intervention Strategies
A hypothetical perfect screening and treatment intervention was introduced in the 3 alternative models. We modeled perfect screening and treatment interventions to study the effect of the alternative models independently from limitations in test performance and treatment outcomes. The cohort was assumed to be screened with a perfect test (i.e., sensitivity and specificity for BE and neoplasia of 100%, irrespective of symptomatic and nonsymptomatic patients) at age 65 years. All preclinical cancers were detected and treated depending on the stage of EAC at the time of detection. After screening, 1 of 3 perfect treatment strategies was applied for people with BE. Perfect treatment is defined as an intervention that ensures BE is effectively removed and EAC will not develop during the lifetime of the treated patient. All residual cases of EAC will therefore develop in patients without BE at the time of screening who developed BE and EAC within 15 years after that screening. In the first treatment strategy, all BE patients with or without dysplasia were treated (BE treatment). The second treatment strategy provided no treatment for nondysplastic BE patients but only for LGD and HGD patients (dysplasia treatment). In the final treatment strategy, only HGD patients received treatment (HGD treatment). 
Outcomes
We compared model variants on the outcomes of BE prevalence and EAC incidence by age group. The effectiveness of BE screening and treatment for all 3 treatment strategies was compared by the reduction in EAC incidence and EAC mortality. The efficiency of screening and treatment was examined by comparison of the number of screenings and treatments required, as well as the number needed to screen and treat to prevent 1 EAC case of death. A sensitivity analysis was performed to compare the impact of hypothetical interventions in different age groups.
This study was funded by the National Cancer Institute.
RESULTS
The BE prevalence was highest in the model with regression (3.3% for ages 60-65 years) followed by low progression (2.9% for ages 60-65 years) and high progression (1.3% for ages 60-65 years) ( Figure 2 ).
The differences in EAC incidence and mortality reduction from screening and treating all BE were negligible between the 3 models (Table 2) but were more pronounced for dysplasia and HGD treatment. The maximum clinical incidence reduction was greatest in the strategy incorporating treatment of all patients with BE (58%-62%), followed by dysplasia treatment (26%-42%) and HGD treatment (4%-13%).
Differences in the EAC development in the untreated BE population directly reflect differences in the progression rates between the models. In case of treatment limited to dysplasia, 7.5% of the ND BE developed into EAC in the high-progression model, whereas in the low-progression and the regression models, less than 3.5% developed into EAC (Figure 3 ).
The number of treatments differs in each model because this is influenced by the variation in BE prevalence. As a consequence, the number of treatments required to treat all patients with BE is 3-fold higher in the regression model compared with the high-progression model, which requires the fewest number of treatments. Given this variation in number of treatments and the minor differences in the effectiveness of screening and treatment, large differences are seen in the numbers needed to treat to prevent 1 EAC case (NNT/case) and numbers needed to treat to prevent 1 EAC death (NNT/death). The all-BE treatment strategy is most efficient in the high-progression model (NNT/death is 8.5), followed by the lowprogression model (NNT/death is 19.1) and the regression model (NNT/death is 24.3) ( Figure 4 ). Almost no differences in the efficiency of HGD treatment are found among the 3 models.
Additional sensitivity analyses were performed on the age of initial screening and treatment. In the case of treatment of all BE, the incidence and mortality reductions were inversely associated with the initial age of screening; BE treatment in older age groups was less effective. Differences between the models in mortality reduction ranged from 5% to 34% for intervention age 75 years compared to intervention age 55 years. The differences between the models in NNT/ death ranged from 2.1-to 2.9-fold for the different intervention ages (online appendix, Table A3 ). 
DISCUSSION
This study demonstrates that the current uncertainty surrounding BE progression is unlikely to lead to large differences in estimates of the effectiveness of BE screening and treatment in the strategy of treatment for all patients with BE. However, if treatment is restricted to BE patients with dysplasia, treatment effectiveness varies widely and is dependent on BE progression assumptions. Furthermore, the resources required to gain that effectiveness vary considerably when treating all BE: screening and treating of all BE requires up to 3 times more patients to be treated per death prevented in a situation with regression compared with a situation with high progression. Finally, the smaller number of patients treated when limiting therapy to patients with dysplasia results in smaller differences in the efficiency of treatment between the models when following the patients for a 15-year period.
BE prevalence differs considerably between the models (1%-3% at ages 60-65 years). This difference is explained by differences in assumptions about BE progression. In the case of low progression, a higher BE prevalence is needed compared with high progression to calibrate to the same SEER-based cancer incidence. Because of this dependency, the real progression rate parameter could be estimated if the real BE prevalence in the population would be known and vice versa. Unfortunately, estimates for both parameters differ widely, and estimates in all 3 models lie well within the plausible range published in the literature. Based on published data, the estimated plausible range for BE prevalence is assumed to be within 1.6% to 6.8%, 21 which overlaps our simulation estimates. Our study shows that with a high BE prevalence, there are more treatments required to obtain the same effectiveness of treatment in terms of cancer and death reduction. Screening and treatment interventions for all BE patients or patients with dysplasia result in a larger reduction in EAC incidence than EAC mortality due to the risk of death from competing causes. When performing screening and limiting treatment to HGD patients, just a small proportion of cancer incidence and deaths is reduced because of HGD treatment. Hence, a large proportion of death reduction from this strategy is due to early detection of malignancies at screening.
We focused on the potential effectiveness of treatment using simulation modeling of a hypothetical perfect intervention. We have used the approach that mirrors the maximal clinical incidence reduction (MCLIR) 1 ; this theoretical approach identifies how and where differences in model structures manifest in their results. Here the estimated incidence and mortality reductions correspond to the maximum possible clinical benefit in EAC incidence achievable by screening and treatment of BE lesions. We did not implement a ''real-life'' intervention in our model because there is a paucity of data on treatment results of LGD and BE. Our point was merely to illustrate the impact of uncertainty in natural history on screening and treatment of BE in general. However, our study results can be generalized to (cost-) effectiveness of real-life interventions: the relative impact of the differences between model structures in this study can be directly translated to relative differences in the effectiveness of real-life interventions.
Previous research found that both the progression rate from BE to EAC and the BE prevalence in the population were among the variables causing at least 10% variation in the incremental cost-effectiveness ratio, 2 while our studies suggest that up to 70% variation in the effectiveness of treatment interventions may be due to differences in progression assumptions and BE prevalence. Two large cost-effectiveness studies on the treatment of BE have been published. 3, 4 Both studies concluded that cost-effective surveillance and treatment scenarios are present for treatment of HGD, but treatment of ND and LGD BE is far more expensive and not cost-effective. When comparing differences in NNT/death and NNS/death between our models with literature for other screening programs, we found that outcomes for the efficiency of screening in terms of numbers needed to invite (NNI) are reported for breast cancer screening. A recent meta-analysis reported 1904 NNI/death, with a large 95% confidence interval between 929 and 6378 NNI/death. 5 Thus, the reported variation of NNI/death within the 95% confidence interval holds a 7-fold variation, while our results reported variation between models up to 3-fold for the NNT/ death. Modeling studies reporting the influence of the uncertainty of input parameters and model structures on cancer screening also showed considerable differences for the effectiveness of screening. The study that compared various models with different structures and input assumptions for the simulation of colonoscopy screening showed that the MCLIR after disease removal at ages 65 to 80 years varied from 51% to 90% between models, 6 implying a difference of 80% in incidence reduction between models. In our study, the largest differences were seen in case of HGD treatment, resulting in a difference of 230% in incidence reduction. A recent study investigated the benefits and harms of computed tomography lung cancer screening strategies by 5 comparative simulation models. Differences in modeling results for the number of persons who were no longer dying of lung cancer varied between 177 and 863 per 100,000 individuals, 7 which is a 5-fold difference in mortality reduction. Our study showed a maximum of 1.6-fold difference between the mortality reduction of the models.
This study has 3 limitations that are noteworthy. First, for each model, additional parameters apart from the BE incidence must be recalibrated. Therefore, some differences in model outcomes might be due to slightly different estimates in parameters such as preclinical sojourn times and the dysplastic proportion in the BE population. When calibrating the high-progression model, the model compensates by shortening the sojourn times. This resulted in Figure 4 Representation of the number needed to treat to prevent 1 esophageal adenocarcinoma (EAC) death for each model in each treatment strategy. BE, Barrett's esophagus; HGD, high-grade dysplasia. a high percentage of dysplastic patients in the total BE population. Thus, it was not feasible to reach the main calibration target of a high progression in combination with a low proportion of LGD in BE (calibration target of 9%). Consequently, optimization of the high-progression model resulted in a high proportion of LGD patients (17%). However, most differences in these other parameters are small (online appendix, Table A2 ) and therefore not likely to greatly influence results.
Second, this analysis is restricted to white males. We focused on this group because most published data are derived from this group, and including nonwhites and females to the analyses would add more uncertainty to the models. Third, for this analysis, we have focused on differing progression rates from BE to EAC and have not accounted for other changes and uncertainties in variables, such as secular trend assumptions and assumptions concerning the preclinical sojourn times. Incorporating a secular trend could have effects on different parts of the model. It is not known whether these effects would be totally or partly caused by an increase in BE incidence or in a higher progression toward EAC in the BE population; thus, we decided not to model these effects. Since the preclinical to clinical sojourn time is a small part of the total BE to EAC sojourn time sequence, the impact of varying the preclinical sojourn time is expected to be small compared with the current analysis.
Our analysis highlights the importance of research to diminish the uncertainty in BE prevalence and progression rate to malignancy in BE patients. Because these variables are closely correlated, a reliable estimate of either would substantially reduce current uncertainty. Identification of the progression rate to malignancy using a BE surveillance cohort to observe cancer development is difficult. Therefore, we suggest a study to accurately estimate BE prevalence since this type of study does not require long-term follow-up and would be able to provide an answer to this important question in a shorter time frame.
In conclusion, our analysis illustrates that there is great uncertainty in the efficiency of treatment for Barrett's esophagus despite small variation in the effectiveness of therapy. This is due to the large variation in the numbers needed to treat based on the differing progression rates. Limiting treatment to patients with BE and HGD reduces the variability induced by uncertainty in progression. Estimates of the effectiveness and efficiency of BE screening and treatment will be highly speculative until this uncertainty is resolved.
